To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).
Morganti, A. G., Massaccesi, M., Caravatta, L., Macchia, G., Picardi, V., Deodato, F., Ippolito, E., Mignogna, S., Ferro, M., Cilla, S., Mattiucci, G. C., Valentini, V., Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study, <<ANTICANCER RESEARCH>>, 2013; 33 (10): 4585-4589 [http://hdl.handle.net/10807/51979]
Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study
Morganti, Alessio Giuseppe;Massaccesi, Mariangela;Caravatta, Luciana;Macchia, Gabriella;Picardi, Vincenzo;Deodato, Francesco;Ippolito, Edy;Mignogna, Samantha;Ferro, Milena;Cilla, Savino;Mattiucci, Gian Carlo;Valentini, Vincenzo
2013
Abstract
To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
